Skip to Content
Get key facts and figures about chronic dry eye

Ciprofloxacin ophthalmic Pregnancy and Breastfeeding Warnings

Ciprofloxacin ophthalmic is also known as: Ciloxan

Ciprofloxacin ophthalmic Pregnancy Warnings

Animal studies have failed to reveal evidence of embryotoxicity or teratogenicity. In rabbits, gastrointestinal toxicity was observed with oral doses and resulted in maternal weight loss and increased incidence of abortion (but no teratogenicity); no maternal toxicity (and no embryotoxicity or teratogenicity) observed with IV doses. There are no controlled data in human pregnancy. Systemic ciprofloxacin distributes into amniotic fluid. Levels reported were 57% (at 2 to 4 hours postdose) to 1000% (at 10 to 12 hours postdose) of that found in maternal serum. Cartilage damage and arthropathy have been reported in immature animals of various species giving rise to concern over possible toxic effects on human fetal bone formation. Limited data indicate that systemic absorption after ophthalmic administration is extremely low (between 2.5 and 5 ng/mL). AU TGA pregnancy category B3: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans. US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus; according to some experts, it is preferable to avoid use during pregnancy (as a precaution). AU TGA pregnancy category: B3 US FDA pregnancy category: C

See references

Ciprofloxacin ophthalmic Breastfeeding Warnings

Oral ciprofloxacin is excreted in human breast milk. Limited data indicate that systemic absorption after ophthalmic administration is extremely low (between 2.5 and 5 ng/mL). Traditionally, systemic fluoroquinolones have not been used in infants due to concern over toxic effects on their developing joints; however, some studies suggest risk is low. Absorption of the small amounts of fluoroquinolones in milk may be blocked by the calcium in milk; data insufficient to prove or disprove.

Caution is recommended. Excreted into human milk: Unknown Excreted into animal milk: Data not available Comments: -Maternal use of an ophthalmic drop containing this drug poses negligible risk for a nursing infant. -Placing pressure over the tear duct by the corner of the eye for at least 1 minute then removing excess solution with an absorbent tissue substantially reduces the amount of drug that reaches the breast milk after using eye drops.

See references

References for pregnancy information

  1. Cerner Multum, Inc. "Australian Product Information." O 0
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. "Product Information. Ciloxan (ciprofloxacin ophthalmic)." Alcon Laboratories Inc, Fort Worth, TX.

References for breastfeeding information

  1. "Product Information. Ciloxan (ciprofloxacin ophthalmic)." Alcon Laboratories Inc, Fort Worth, TX.
  2. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  4. Cerner Multum, Inc. "Australian Product Information." O 0

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.